Feb 06 2012
ABIOMED, Inc. engages in the research, development and sale of medical devices that provide circulatory support to acute heart failure patients across the continuum of care in heart recovery. Its productrs include Impella 2.5 catheter, a percutaneous micro heart pump with integrated motor and sensors for use in interventional cardiology, and Impella 5.0 catheter and impella LD, which are percutaneous micro heart pumps with integrated motors and sensors for use primarily in the heart surgery suite. The Company also manufactures and sells the AB5000 circulatory support system and the BVS 5000 biventricular support system for temporary support of acute heart failure patients in profound shock, including patients suffering from cardiogenic shock after a heart attack, post-cardiotomy cardiogenic shock, or myocaditis. In addition, it provides Abiocor implantable replacement heart, a self-containe
Michael Minogue, CEO of medical device maker ABIOMED, appeared on CNBC’s “Mad Money” on February 6th, 2012. The executive discussed his company’s earnings and whether its stock [ABMD 20.94 0.17 (+0.82%) ], selling for 5.8 times next year’s sales, still has room to run. Watch the video to see Cramer’s full interview.
